Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

805.23 -20.68 (-2.50%)
Official Closing Price Updated: 7:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Eli Lilly Stock Popped on Thursday
Via The Motley Fool
Earnings Scheduled For February 6, 2025
Via Benzinga
Eli Lilly Unusual Options Activity
Via Benzinga
Trump Focused On 10-Year Yield And Not On The Fed, Slower AI Growth Fears Weigh On Arm Stock
To gain an edge, this is what you need to know today. 
Via Benzinga
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Interest Rates Political
The 9 Best Stocks to Buy Now in February (2025)
Via The Motley Fool
In 2025, the pharmaceutical industry is ripe for M&A
Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment for mergers and acquisitions 
Via Equities.com
Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat
Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments. 
Via Stocktwits
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025. 
Via Investor's Business Daily
Exposures Product Safety
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines
Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches. 
Via Benzinga
Eli Lilly’s Q4 2024 Revenue Surges By 45% To $13.53 Billion
Eli Lilly and Company reported a robust revenue growth of 45% in Q4 2024, reaching $13.53 billion, driven by increased volume from key products. 
Via Talk Markets
Topics Stocks / Equities
Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales Miss
Eli Lilly earnings beat Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Eli Lilly (NYSE:LLY) Reports Q4 In Line With Expectations, Full-Year Outlook Slightly Exceeds Expectations
Global pharmaceutical company Eli Lilly (NYSE:LLY) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The company’s full-year revenue guidance of... 
Via StockStory
US Stocks Likely To Open Higher Ahead Of Amazon's Earnings: 'Buy The Dip' Mentality Remains Prevalent, Says Analyst
U.S. stock futures rose on Thursday following Wednesday's advances as investors digest tariff pauses amid earnings reports. 
Via Benzinga
Topics World Trade
Exposures Tariff
Eli Lilly Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
Markets Jump Ahead Of The Close; QCOM, F, ARM Beat Estimates After
Market indexes put in a fine showing at the closing bell today, climbing in the final minutes of trading across major indexes and ending the day at or near session highs. 
Via Talk Markets
Topics Stocks / Equities
Viking Therapeutics Plummeted 10% On Its Earnings Report. Here's Why.
Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates. 
Via Investor's Business Daily
Eli Lilly Bulls Take Charge Ahead Of Q4 — Can It Reach $1000?
Eli Lilly (LLY) reports Q4 earnings Thursday. LLY stock up 8.22% YTD. Chart shows strong bullish momentum with potential for further gains. Analysts see 27% upside. 
Via Benzinga
What To Expect When Eli Lilly Reports Q4 Earnings On Thursday?
Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024. 
Via Benzinga
Earnings Miss? Amgen’s Dividend Still a Bright Spot
Via MarketBeat
Exposures Product Safety
What To Expect From Eli Lilly’s (LLY) Q4 Earnings
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow morning. Here’s what to expect. 
Via StockStory
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors question trial protocols and transparency as Novo plans a new study. 
Via Benzinga
3 Magnificent Stocks to Buy and Hold Forever
Via The Motley Fool
Market Briefing For Monday, Feb. 3, 2025
As to the market, at the moment it is being reactive to tariffs, news of which of course aborted the effort at finishing January on a strong note. It's that basic. 
Via Talk Markets
Topics Commodities Stocks / Equities World Trade
Exposures Tariff
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
Via The Motley Fool
Got $1,000? 2 Top Growth Stocks to Buy Right Now
Via The Motley Fool
3 Unstoppable Stocks You Can Buy and Hold for the Rest of Your Life
Via The Motley Fool
MarketBeat Week in Review – 01/27 - 01/31
Stocks posted slight gains for the week as investors shrugged off concerns over China's DeepSeek open-source API and the latest reading on inflation 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure. 
Via Benzinga
5 Top Stocks to Buy in February 2025
All of them have great upside. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS